MEDICAMENT RELEASE FROM OINTMENT BASES .5. NAPROXEN INVITRO RELEASE AND INVIVO PERCUTANEOUS-ABSORPTION IN RABBITS

被引:12
作者
RAHMAN, MS
BABAR, A
PATEL, NK
PLAKOGIANNIS, FM
机构
[1] The Cosmetic Studies Center, Division of Pharmaceutics and Industrial Pharmacy, Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Brooklyn, NY
关键词
D O I
10.3109/03639049009104409
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The in- vitro release of Naproxen from various ointment bases, including a water-washable base with the drug in the water phase (I) and the drug in the oil phase (II), a hydrophilic base with the drug in the water phase (III), and the drug in the oil phase (IV), and an anhydrous ointment (V), a gel (VI) and a modified University of California (U.C.H.) base (VII) were studied. In addition, the effects of various additives (urea, ethanol, dimethyl sulfoxide and polyethylene glycol-400) on the release of Naproxen from formulations (I) and (II) were determined. Low concentrations of urea and ethanol in the formulations increased the release of the drug from both these bases, however, higher concentrations adversely affected the release of the drug. While dimethyl sulfoxide (DMSO) had no significant effect on the drug release, the inclusion of polyethylene glycol-400 in both bases decreased the release of Naproxen. The percutaneous absorption of Naproxen from the waterwashable base (drug in the oil phase) and hydrophilic base (drug in the oil phase) were studied by applying the ointments on rabbit's skin. It was observed that the bioavailability of Naproxen from the hydrophilic base was slightly greater than that from the water-washable base, and that DMSO had no effect in enhancing the in-vivo release of Naproxen from the ointments evaluated. Using the in-vivo data, the absorption and elimination rate constants, the half-life and AUC were calculated. © 1990 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.
引用
收藏
页码:651 / 672
页数:22
相关论文
共 24 条
[11]   SOLVENCY AND HYDROGEN BONDING INTERACTIONS IN NONAQUEOUS SYSTEMS [J].
HIGUCHI, T ;
RICHARDS, JH ;
DAVIS, SS ;
KAMADA, A ;
HOU, JP ;
NAKANO, M ;
NAKANO, NI ;
PITMAN, IH .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1969, 58 (06) :661-&
[12]  
Higuchi T, 1960, J SOC COSMET CHEM, V11, P85
[13]  
HILL HF, 1973, P S LONDON, P47
[14]  
HOLLANDER JL, ARTHRITIS ALLIED CON
[15]  
KATZ WA, 1977, RHEUMATIC DISEASES D, P390
[16]  
MARKKU A, 1977, J PHARM SCI, V66, P433
[17]  
MIZUSHIMA Y, 1975, BIOCH PHARM, V24
[18]   NAPROXEN IN RHEUMATOID-ARTHRITIS [J].
MOWAT, AG ;
ANSELL, BM ;
GUMPEL, JM ;
HILL, HFH ;
HILL, AGS ;
STOPPARD, M .
ANNALS OF THE RHEUMATIC DISEASES, 1976, 35 (06) :498-501
[19]  
Niazi S, 1979, TXB BIOPHARMACEUTICS
[20]   OPEN TRIAL OF NAPROXEN IN RHEUMATOID-ARTHRITIS PATIENTS WITH SIGNIFICANT ESOPHAGEAL, GASTRIC, AND DUODENAL LESIONS [J].
ROTH, SH ;
BOOST, G .
JOURNAL OF CLINICAL PHARMACOLOGY, 1975, 15 (04) :378-384